William J. Zavadoski

Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects

Karen L. Houseknecht, Alan S. Robertson, William J. Zavadoski et al. · Neuropsychopharmacology · 2006 · 240 citations

Obesity, Metabolic Syndrome, Whole-body Insulin Resistance +13

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 114 citations · Full text

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

Sumeet A. Khetarpal, Xuemei Zeng, John S. Millar et al. · Nature Medicine · 2017 · 111 citations · Full text

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1

Robert L. Dow, Jiancheng Li, Michael P. Pence et al. · ACS Medicinal Chemistry Letters · 2011 · 100 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +16

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

Jianxin Yang, Margit MacDougall, Michael T. McDowell et al. · BMC Genomics · 2011 · 82 citations · Full text